HCV EU infographic
Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.
Our latest market snapshot offers an introduction to the real world patient data collected by our Therapy Watch HCV study, providing you with an overview of HCV patient profiles and treatment pathways.
Click here to view our infographic »
Sign up to receive Rapport Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »
Pricing wars heat up over hepatitis C drugs
The race for better hepatitis C treatments is in full swing with the approval of another all-oral drug regimen. The U.S. Food and Drug Administration (FDA) approved AbbVie’s new multi-drug combination, Viekira Pak, on December 19 last year, heightening the competition in the hepatitis C arena.
Sovaldi, Gilead’s oral treatment for hepatitis C costing $1,000 per pill, was cleared in the U.S. in December 2013, followed by the FDA approval of Harvoni at a cost of $1,125 per pill in October of last year. These two new Gilead drugs were launched at prices of $84,000 and $94,500 respectively for a 12-week regimen. In a battle to grab market share, AbbVie’s rival hepatitis C drug Viekira Pak costs $83,319 for a standard 12-week regimen.